卵巢癌患者血清miR-200家族和miR-100检测的临床价值

目的 探讨血清microRNA的表达差异在卵巢癌诊断和治疗中的临床价值.方法 收集149例卵巢肿瘤患者和30例健康体检者,采用qRT-PCR检测受检者血清miR-200a、miR-200b、miR-200c和miR-100的表达情况,对检测结果进行统计学分析.结果 miR-200a、miR-200b和miR-200c在卵巢癌患者血清中表达水平均高于正常对照者,而miR-100在卵巢癌患者血清中表达水平低于对照组,且差异均有统计学意义（P均＜ 0.001）.miR-200a、miR-200b、miR-200c及miR-100在良性肿瘤患者与正常对照者血清中表达水平差异均无统计学意义（P均＞ 0.05）.miR-200a、miR-200b和miR-200c在透明细胞癌的表达水平明显高于浆液性和黏液性癌,且差异均有统计学意义（P均＜ 0.05）.miR-200b在浆液性癌中的表达水平高于黏液性癌,miR-200c在透明细胞癌中的表达水平高于子宫内膜癌,且差异均有统计学意义（P均＜ 0.05）.结论 血清miR-200家族的表达可用于卵巢癌的诊断、疗效监测及预后评估.

Clinical value of serum miR-200 family and miR-100 detection in ovarian cancer diagnosis

Objective To study the clinical value of microRNA in the diagnosis of ovarian cancer. Methods 149 ovarian tumor patients and 30 healthy people were collected. The expression of serum miR-200a, miR-200b, miR-200c and miR-100 were detected by qRT-PCR, and the results were analyzed statistically. Results The expression of serum miR-200a, miR-200b and miR-200c in ovarian cancer patients were all higher than that of in control group, the expression of the serum miR-100 in ovarian benign tumor patients was lower than that of in control group, and the differences all had statistical significance （Pall〈 0.001 ）. There were no statistical significance in the differences of miR-200a, miR-200b, miR-200c and miR-100 levels between ovarian benign tumor patients and control group （Pall〉 0.05）. The expression levels of serum miR-200a, miR-200b and miR-200c in clear cell carcinoma patients were all higher than that of in both serous and mucinous patients, and the differences all had statistical significance （Pall〈 0.05）. The expression level of miR-200b in serous carcinomas patients was higher than that of in mucinous patients, and the expression level of miR-200c in clear cell carcinoma patients was higher than that of in endometrioid carcinomas, and the differences all bad statistical significance （Pall〈 0.05）. Conclusion The expression of serum miR- 200 family can be used for early diagnosis and evaluation of the curative effect and recurrent clinical value in ovarian cancer.